Delve into the field of PARP inhibitors, a class that has gained traction in ovarian, breast, and prostate cancers.

Learn more about a new experimental procedure that uses cancer cells’ DNA repair system against itself to make drug-resistant ...

Cancer cells survive by repairing damage to their DNA—even damage that would normally be fatal. One of their most important ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

Poly(ADP‐ribose) polymerases (PARPs) are a family of enzymes that play a crucial role in maintaining genomic integrity by detecting DNA damage and facilitating its repair. By catalysing the covalent ...

PARP inhibitors revolutionize ovarian cancer treatment, offering targeted therapy options and improved outcomes for patients with specific genetic markers. Niraparib approved for all-comers whose ...

Researchers at AACR described the development of a classifier that identified a proportion of tumor samples with HRD that did not have BRCA1/2 mutations.

The article by George et al entitled “Phase II Trial of the PARP Inhibitor, Niraparib, in BAP1 and Other DNA Damage Response Pathway-Deficient Neoplasms” (JCO ...

The investigational agent IMNN-001 is demonstrating promising potential to extend survival in patients with advanced ovarian ...

While the safety was more manageable, questions remain about whether the combination would best antibody-drug conjugate ...

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...